Currently Funded Venture Grants
CurePSP provides seed funding to investigators who have innovative ideas and that need to establish or confirm proof of concepts in order to qualify for larger funding sources. Please find below a list of currently funded researchers.
Newly Funded 2020
Dr. Rueben Das, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
Connecting GWAS signal in TAU Locus to Effector Variant in Tauopathies
Dr. Geidy E. Serrano, Banner Sun Health Research Institute, Sun City, AZ
Single-Whole-Cell Characterization in Progressive Supranuclear Palsy
Dr. Amanda L. Woerman, University of Massachusetts, Amherst, MA
Investigating PSP and CBD Tau Strain Biology to Support Novel Diagnostic Development
Dr. John M. Ringman, Keck School of Medicine at the University of Southern California, Los Angeles, CA
Genotyping Familial Progressive Supranuclear Palsy
Dr. Lukasz Joachimiak, Center for Alzheimer’s and Neurodegenerative Diseases, UT Southwestern Medical Center, Dallas, TX
Structural Basis for Tau Strain Conformation in CBD and PSP
Dr. Kenneth Matthew Scaglione, Molecular Genetics and Microbiology, Duke University, Durham, NC
Small Molecule Regulation of a Protein Quality Control E3 to Treat PSP
Dr. Mark Cooper, Institute of Neurology, Dept of Clinical and Movement Neurosciences, University College London, London, England
The Influence of TRIM11on Tau, Aggregation, Release and Propagation
Dr. David C. Butler, Neural Stem Cell Institute, Regenerative Research Foundation, Rensselaer, NY
Bifunctional Intrabodies to Lower Tau
Ongoing Funded Grants
Dr. Maria-Elena Avale, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Buenos Aires, Argentina
Dissecting Neuronal Dysfunctions Under 3R:4R Tau Isoforms Imbalance
Dr. Gal Bitan, University of California, Los Angeles
Biomarkers In Brain-Derived Blood Exosomes For Improved PSP Diagnosis
Dr. Giovanni Coppola, University of California, Los Angeles
Member of the PSP Genetics Consortium. The goal of this project is to create and maintain a dedicated cloud environment and database to host phenotypic and genetic data from the PSP Genetics Consortium cohort.
Dr. Todd J. Cohen, The University of North Carolina at Chapel Hill, NC
Uncovering Unique Tau Profiles That Distinguish PSP From Other Tauopathies
Dr. Thomas Koeglsperger, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Munich, Germany
Investigating the Role of Syntaxin 6 (STX6) for Tau Protein Cell-to-Cell Transmission
Dr. Xiaobo Mao, The Johns Hopkins University School of Medicine, Baltimore, MD
The Role of TTR1 in Mediating Tau Spread In-Vitro and In-Vivo
Dr. Edward A. Burton, University of Pittsburgh, PA
Functional Evaluation of PSP GWAS Genes in a Tauopathy Model In-Vivo
Dr. Michelle S. Troche, Columbia University, New York, NY
The Stephen N. Jasperson Study: Developing Treatments for Swallowing and Communication Deficits in PSP
Dr. Jori Fleisher, Rush University, Chicago, IL
Care Where it Counts; Support to Reduce Isolation and Ensure Well-Being for Patients and Caregivers
Dr. John W. Steele, Humboldt State University, Arcata, CA
iCRISPRi in Human Neurons and Glia to Elucidate Selective Turnover of Tau
Dr. Lars Ittner, University of New South Wales, Australia
Defining a Novel Drug Target for PSP and CBD
Dr. Tsuneya Ikezu, Boston University School of Medicine, Boston, MA
Evaluation of STX6 silencing on the novel AAV-based PSP mouse model